Dostarlimab (Jemperli)

General information

Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Toxicity management

• Immunotherapy toxicity management

Diseases for which it is established

• Endometrial cancer

Diseases for which it is used

• MSI-H or dMMR solid tumors (tissue-agnostic)

History of changes in FDA indication

Endometrial cancer

• 4/22/2021: Granted accelerated approval for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. (Based on GARNET)
• 2/9/2023: Approved for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. (Based on GARNET)

MSI-H or dMMR tumors (tissue-agnostic)

• 8/17/2021: Granted accelerated approval for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. (Based on GARNET)

History of changes in EMA indication

• 4/21/2021: Initial conditional authorization at Jemperli.

Also known as

• Code name: TSR-042
• Generic name: dostarlimab-gxly
• Brand name: Jemperli